Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis (Q34991509)

5 August 2017

1 reference

title

Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis (English)

1 reference

relapsing-remitting multiple sclerosis

5 August 2017

0 references

0 references

author name string

Dene Simpson

series ordinal

1

1 reference

5 August 2017

Stuart Noble

series ordinal

2

1 reference

5 August 2017

Caroline Perry

series ordinal

3

1 reference

5 August 2017

publication date

1 January 2002

1 reference

5 August 2017

1 reference

5 August 2017

volume

16

1 reference

5 August 2017

issue

12

1 reference

5 August 2017

page(s)

825-850

1 reference

Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained

5 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00023210-200216120-00004

Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years

21 January 2018

1 reference

12 December 2020

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

1 reference

12 December 2020

Therapeutic strategies in multiple sclerosis. I. Immunotherapy

1 reference

12 December 2020

Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts

1 reference

12 December 2020

BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?

1 reference

12 December 2020

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

1 reference

12 December 2020

Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen

1 reference

12 December 2020

Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis

1 reference

12 December 2020

Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein

1 reference

12 December 2020

Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients

1 reference

12 December 2020

What is new in the treatment of multiple sclerosis?

1 reference

12 December 2020

Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide

1 reference

12 December 2020

International consensus statement on the use of disease-modifying agents in multiple sclerosis

1 reference

12 December 2020

Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS.

1 reference

12 December 2020

MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients

1 reference

12 December 2020

Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Are clinical trials of therapeutic agents for MS long enough?

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Multiple sclerosis: side effects of interferon beta therapy and their management

1 reference

12 December 2020

Multiple sclerosis and its treatment

1 reference

12 December 2020

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells

1 reference

12 December 2020

Randomized controlled trials to assess therapies for multiple sclerosis

1 reference

12 December 2020

Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells

1 reference

12 December 2020

Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease

1 reference

12 December 2020

Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis

1 reference

12 December 2020

Cytokine production in T lymphocyte-microglia interaction is attenuated by glatiramer acetate: a mechanism for therapeutic efficacy in multiple sclerosis

1 reference

12 December 2020

The economics of multiple sclerosis. Distribution of costs and relationship to disease severity

1 reference

12 December 2020

Therapeutic developments in multiple sclerosis

1 reference

12 December 2020

The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections

1 reference

12 December 2020

Why treat early multiple sclerosis patients?

1 reference

12 December 2020

Drug treatment of multiple sclerosis

1 reference

12 December 2020

Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment

1 reference

12 December 2020

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

Systemic reaction to glatiramer acetate

1 reference

12 December 2020

Copolymer 1 from the laboratory to FDA.

1 reference

12 December 2020

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

Clinical trials of copolymer I in multiple sclerosis

1 reference

12 December 2020

Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients

1 reference

12 December 2020

Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment.

1 reference

12 December 2020

Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses

1 reference

12 December 2020

Lymphadenopathy in patients with multiple sclerosis undergoing treatment with glatiramer acetate

1 reference

12 December 2020

Copolymer-1-induced inhibition of antigen-specific T cell activation: interference with antigen presentation

1 reference

12 December 2020

Progress in determining the causes and treatment of multiple sclerosis

1 reference

12 December 2020

Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1

1 reference

12 December 2020

Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications

1 reference

12 December 2020

Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation.

1 reference

12 December 2020

Glatiramer acetate in the treatment of multiple sclerosis

1 reference

12 December 2020

Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules

1 reference

12 December 2020

Mechanisms of immunomodulation by glatiramer acetate

1 reference

12 December 2020

The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease

1 reference

12 December 2020

Treatment of multiple sclerosis with the interferon-betas: comparative risks and benefits

1 reference

12 December 2020

Risk-benefit assessment of glatiramer acetate in multiple sclerosis

1 reference

12 December 2020

Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone

1 reference

12 December 2020

Mechanisms of action of glatiramer acetate in multiple sclerosis

1 reference

12 December 2020

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

1 reference

12 December 2020

Differentiation of multiple sclerosis subtypes: implications for treatment

1 reference

12 December 2020

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

12 December 2020

Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis

1 reference

12 December 2020

T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies

1 reference

12 December 2020

Choosing drug therapy for multiple sclerosis. An update.

1 reference

12 December 2020

Lipoatrophy associated with glatiramer acetate injections for the treatment of multiple sclerosis.

1 reference

12 December 2020

Autoimmune pathogenesis of multiple sclerosis: role of autoreactive T lymphocytes and new immunotherapeutic strategies

1 reference

12 December 2020

Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis

1 reference

12 December 2020

Extended use of glatiramer acetate (Copaxone) for MS

1 reference

12 December 2020

A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy

1 reference

12 December 2020

Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules

1 reference

12 December 2020

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

Considerations in the treatment of relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity.

1 reference

12 December 2020

Binding of copolymer 1 and myelin basic protein leads to clustering of class II MHC molecules on antigen-presenting cells

1 reference

12 December 2020

Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking

1 reference

12 December 2020

Multiple sclerosis treatment 2001.

1 reference

12 December 2020

Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics

1 reference

12 December 2020

Human and murine CD4 T cell reactivity to a complex antigen: recognition of the synthetic random polypeptide glatiramer acetate

1 reference

12 December 2020

Safety profile of copolymer 1: analysis of cumulative experience in the United States and Israel.

1 reference

12 December 2020

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

1 reference

12 December 2020

Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1

1 reference

12 December 2020

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

1 reference

12 December 2020

10.2165/00023210-200216120-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

5 August 2017

1012992222

0 references

1 reference